Fresh name, real signal
OS Therapies is giving its strategic advisory board a little star power, tapping Dr. Robert “Bob” S. Langer — yes, the Moderna co-founder — to help advise the company.
Why this matters
This isn’t a revenue line item or a clinical readout, but it’s not just window dressing either. For a smaller biotech, landing a heavyweight like Langer can boost credibility, open doors, and make future fundraising or partnership conversations a lot less awkward.
The investor angle
The company said Langer will help management with its listeria oncology program, which means the boardroom is getting a dose of serious scientific cachet. In biotech, reputation can act like social proof on steroids: it doesn’t guarantee success, but it can make the market pay closer attention.
Big picture
No one’s buying shares for an advisory-board press release alone. But when a tiny biotech starts collecting big-name minds, it’s usually trying to tell Wall Street: we’re not just tinkering in the lab — we want to look like a serious contender.